{"prompt": "['aim', 'TM', 'mune', 'THERAPEUTICS', 'A Nestl\u00e9 Health Science Company', 'CLINICAL STUDY PROTOCOL', 'ARC009', 'Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in', 'Children and Adolescents: Real-World, Open-Label, Quality of Life Study', 'Protocol Amendment 1.0 - 11 Apr 2018', 'Reference Numbers: NCT03703791, EudraCT 2018-000326-58', 'Aimmune Therapeutics, Inc.', '8000 Marina Blvd, Suite 300', 'Brisbane, CA 94005', 'United States']['Aimmune Therapeutics, Inc.', 'CLINICAL STUDY PROTOCOL', 'Protocol Title:', 'Peanut Allergy Oral Immunotherapy Study of AR101', 'for Desensitization in Children and Adolescents:', 'Real-World, Open-Label, Quality of Life Study', 'Protocol Identifier:', 'ARC009', 'Phase:', '3b', 'Investigational Product:', 'AR101', 'Sponsor:', 'Aimmune Therapeutics, Inc.', '8000 Marina Blvd, Suite 300', 'Brisbane, CA 94005', 'United States', 'Reference Number:', 'EudraCT 2018-000326-58', 'Sponsor Medical Monitor: Stuart McIntosh, BM BS, MRCS, MD, FFPM', 'Mobile:', '+44 7825 904 651', 'Email:', 'smcintosh@aimmune.com', 'Original Protocol:', '0.0 - 03 Apr 2018', 'Amendments', 'Global:', '1.0 - 11 Apr 2018', 'This study will be conducted according to the Declaration of Helsinki (2013), principles of Good Clinical', 'Practice as described in International Council for Harmonisation guidelines, including the archiving of', 'essential documents, EU Directive 2001/20/EC (the Clinical Trials Regulation), EU Directive', '2005/28/EC (Good Clinical Practice Directive), and local applicable legislation including but not limited', 'to the UK SI 2004/1031 Medicines for Human Use (Clinical Trials) Regulations 2004 as amended.', 'Confidentiality Statement', 'The information contained in this document and all information provided to you related to AR101 are the', 'confidential and proprietary information of Aimmune Therapeutics, Inc. (\"Aimmune\"; Aimmune', 'Confidential Information) and except as may be required by federal, state, or local laws or regulations,', 'may not be disclosed to others without prior written permission of Aimmune. However, the investigator', 'may disclose such information to supervised individuals working on AR101, provided such individuals', 'agree to be bound to maintain the confidentiality of such information.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 2 of 122', 'SYNOPSIS', 'Title of Study: Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and', 'Adolescents: Real-World, Open-Label, Quality of Life Study', 'Short Title: AR101 Health-Related Quality of Life (HRQOL) Study in Peanut-Allergic Subjects', 'Protocol Identifier: ARC009', 'EudraCT: 2018-000326-58', 'Phase of Development: 3b', 'Number of Subjects: Approximately 200', 'Study Centers: Approximately 45 in Europe', 'Purpose of the Study: To compare the HRQOL of AR101 characterized oral desensitization', 'immunotherapy (CODITT) in combination with standard of care (peanut avoidance, education) versus', 'standard of care alone in peanut-allergic subjects aged 4 to 17 years, inclusive. The HRQOL of', 'parents/caregivers will also be assessed.', 'Study Objectives:', 'Primary:', 'To assess proxy- and self-reported disease-specific HRQOL of peanut-allergic subjects aged 4 to', '17 years, inclusive, receiving AR101 in combination with standard of care versus standard of care', 'alone for approximately 18 months', 'Secondary:', 'Safety and tolerability of AR101', 'To characterize changes over the course of the study in the following:', 'Disease-specific HRQOL of parents/caregivers', 'Relationship between clinical efficacy of AR101 (change in level of sensitization to peanut allergen)', 'and HRQOL of subjects and parents/caregivers', 'Exploratory:', 'To assess the following:', 'Self-reported assessments of control and confidence; reassurance, worry, and severity of allergic', 'reactions based on food challenge outcomes; and overall HRQOL', 'Changes in nondisease-specific measures of HRQOL, anxiety, and depression in subjects and', 'parents/caregivers', 'Health state utility estimates for economic analysis', 'Changes in peanut skin prick test (SPT) mean wheal diameters associated with AR101 treatment', 'Changes in control of pre-existing concomitant atopic disease (asthma, allergic rhinitis, atopic', 'dermatitis)', 'Relationship between basophil activation, clinical efficacy of AR101, and changes in HRQOL', 'AR101 treatment experience among subjects and parents/caregivers', 'Study Design:', 'This is a phase 3b, randomized, open-label, European study of the HRQOL of AR101 in combination with', 'standard of care (AR101 herein) compared with standard of care alone in approximately 200 peanut-allergic', 'subjects aged 4 to 17 years, inclusive. Standard of care includes avoidance of peanuts/peanut-containing', 'foods, and education on recognition and management of allergy symptoms and appropriate use of rescue', 'medications (eg, epinephrine auto-injectors). HRQOL of parents/caregivers will also be assessed. The', 'safety and tolerability of AR101 will be evaluated.', 'Eligible subjects will be randomly assigned 2:1 to AR101 treatment or standard of care alone.', 'Randomization will be stratified by age group (4-12 years and 13-17 years). Subjects in both treatment']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 3 of 122', 'groups and their parents/caregivers will have disease-specific and nondisease-specific HRQOL assessments', 'at screening and periodically thereafter.', 'Subjects receiving AR101 treatment will have 3 consecutive AR101 dosing periods before exiting', '(completing) the study: initial dose escalation, up-dosing, and maintenance. Subjects receiving standard of', 'care alone will have approximately 18 months of observation before exiting (completing) the study. Subjects', 'in both treatment groups will have a graded open-label food challenge (OLFC) up to a maximum single', 'highest dose of 1000 mg of peanut protein (2043 mg cumulative), approximately 12 months after', 'randomization.', 'AR101 Treatment Group', 'Initial dose escalation: Subjects randomly assigned to AR101 treatment will begin with a stepwise dose', 'escalation of AR101 (up to 5 single doses of 0.5, 1, 1.5, 3, and 6 mg) administered at 20- to 30-minute', 'intervals as tolerated at the study site.', 'Subjects who tolerate at least 3 mg of AR101 on day 1 will return to the study site on day 2 to receive a', 'single confirmatory 3 mg dose under direct observation. Subjects who tolerate the 3 mg confirmatory', 'dose with no or mild symptoms that are not dose-limiting will begin the up-dosing period.', 'Subjects who do not tolerate at least 3 mg of AR101 on day 1 or day 2 will stop AR101 treatment and', 'discontinue early from the study.', 'Up-dosing: The up-dosing period will be approximately 6 months (22-40 weeks). Dose escalation will', 'occur approximately every 2 weeks. Daily AR101 doses during up-dosing will be 3, 6, 12, 20, 40, 80, 120,', '160, 200, 240, and 300 mg/day. The first dose of AR101 at each new dose level will be administered under', 'direct observation at the study site; the remaining doses at each dose level will be administered daily at home', 'as tolerated. Subjects able to tolerate 300 mg for 2 weeks will begin the maintenance period. Subjects', 'unable to tolerate 300 mg/day for 2 weeks within 40 weeks of up-dosing will stop AR101 treatment and', 'discontinue early from the study.', 'Maintenance: Subjects will continue AR101 daily dosing at 300 mg/day for an additional 12 months', '(52 weeks) with study site visits every 4 weeks. After at least 6 months (up to 7 months) of maintenance', 'treatment (approximately 12 months after randomization/first dose of AR101), subjects will have a graded', 'OLFC up to a maximum single highest dose of 1000 mg of peanut protein (3, 10, 30, 100, 300, 600, 1000 mg', '[2043 mg cumulative]).', 'Subjects who tolerate 1000 mg of peanut protein (2043 mg cumulative) at the OLFC will continue', 'AR101 daily at 300 mg/day and will have the option to consent for a real-world peanut challenge', '(RWPC) within 4 weeks (preferably within 1 week) after the OLFC. During the RWPC, subjects will', 'eat a food containing 500 to 600 mg of peanut protein under direct observation at the study site.', 'Subjects who complete the RWPC (regardless of the outcome) will continue daily maintenance', 'treatment with AR101 at 300 mg/day for a total of 52 weeks of maintenance until study exit.', 'Subjects who tolerate at least 300 mg but < 1000 mg of peanut protein (2043 mg cumulative) at the', 'OLFC or tolerate 1000 mg of peanut protein (2043 mg cumulative) but do not consent to the optional', 'RWPC will continue daily maintenance treatment with AR101 at 300 mg/day for a total of 52 weeks of', 'maintenance until study exit.', 'Subjects who do not tolerate at least 300 mg of peanut protein at the OLFC will stop AR101 treatment', 'and discontinue early from the study.', 'Standard of Care Treatment Group', 'Subjects receiving standard of care alone will have approximately 18 months of observation before study', 'exit, with an OLFC approximately 12 months after randomization. Subjects receiving standard of care alone', 'who complete the OLFC will not have an RWPC.', 'Both Treatment Groups', 'Early discontinuation: Subjects with unresolved adverse events at early discontinuation or who had', 'gastrointestinal (GI) adverse events of interest will have safety follow-up.', 'Subjects who discontinue AR101 treatment early before completing 9 months of maintenance, and their', 'parents/caregivers, will complete relevant follow-up HRQOL questionnaires.', 'Study exit: Subjects with unresolved adverse events at study exit or who had GI adverse events of interest', 'will have safety follow-up. AR101-treated subjects who complete approximately 12 months of maintenance']", "completion": ""}